Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 189Neoplasm Metastasis 19Neoplasms 9Ovarian Neoplasms 8Breast Diseases 6Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Endometrial Neoplasms 4Advanced Breast Cancer 4Neoplasms by Site 3Lung Neoplasms 3Hereditary Sensory and Autonomic Neuropathies 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Recurrence 2Rectal Neoplasms 2Neoplasm, Residual 2Multiple Myeloma 2Melanoma 2Inflammation 2Hematologic Neoplasms 2Fallopian Tube Neoplasms 2Estrogen Receptor-positive Breast Cancer 2

Interventions

Trastuzumab 33pertuzumab 18Docetaxel 16pyrotinib 15Paclitaxel 7Capecitabine 6tucatinib 5Carboplatin 5Ado-Trastuzumab Emtansine 4trastuzumab deruxtecan 3neratinib 3atezolizumab 2Protons 2Neoadjuvant Therapy 2Fulvestrant 2pegfilgrastim 1palbociclib 1margetuximab 1liposomal doxorubicin 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1Taxoids 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Injections 1Hospital Information Systems 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × palbociclib × Breast × Clear all
NCT03709082 2024-03-05

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

University of Kansas Medical Center

Phase 1/2 Terminated
3 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡